|
Jenken Biosciences, Inc., a specialty pharmaceutical company located
in Research Triangle Park, NC, is developing drugs that modulate
cytokine release involved in chronic inflammation-associated organ
damage, a >$10B worldwide market. Our current focus within this
broad opportunity is chronic inflammatory liver disease which includes
chronic hepatitis, cirrhosis and non-alcoholic steatohepatitis (NASH).
The Company’s drug development strategy is to reduce time-to-market
and to lower risk and development costs by re-profiling approved
drugs and their analogs or metabolites which possess favorable toxicological,
pharmacokinetic and effectiveness profiles.
|